SCHEMBL3591331

SCHEMBL3591331

C=CCOC(=O)c1cnc(Cl)nc1N(C)CC1CCC2(CC1)CC2

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.33
CTSL P07711 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
SCN9A Q15858 1/20 0.32
MELK Q14680 2/20 0.31
ALDH1A1 P00352 3/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CSF1R P07333 1/20 0.30
DYRK1A Q13627 1/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
ALOX15 P16050 1/20 0.30
RAB9A P51151 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590097 0.86 CTSS (0.46) CYP3A4CTSLCTSSCTSKMELK
SCHEMBL5570846 0.82 CTSS (0.38) CTSLCTSSCTSKSCN9AMELK
SCHEMBL3601980 0.80 CYP3A4 (0.36) CYP3A4SCN9AALDH1A1TSHRHSD17B10
SCHEMBL3591330 0.77 CYP3A4 (0.34) CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL3591329 0.75 SYK (0.35) CYP3A4ALDH1A1TSHRHSD17B10RAB9A
SCHEMBL3601469 0.70 CYP3A4 (0.50) CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2
SCHEMBL3591335 0.70 SYK (0.34) CYP3A4CTSLCTSSCTSKSCN9A
SCHEMBL3595213 0.69 CTSS (0.44) CYP3A4CTSLCTSSCTSK
SCHEMBL3587062 0.68 CTSS (0.55) CTSLCTSSCTSKMELKCSF1R
SCHEMBL3590094 0.65 CTSS (0.37) CYP3A4CTSLCTSSCTSKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704996-B2 Compounds and compositions useful as cathepsin S inhibitors NOVARTIS AG (CH) 2010-04-27 US disclosed
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2009-02-19 US disclosed
EP-1781623-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS Novartis AG (CH) 2007-05-09 EP disclosed
WO-2006018284-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS NOVARTIS AG (CH) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048230-A1 COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS CTSS, CTSZ, CTSF CYP3A4 2233/4885CTSL 9/4885CTSS 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.